Roche announces FDA approval of new VENTANA PD-L1 assay
Roche today announced approval of the VENTANA PD-L1 (SP142) Assay by the US Food and Drug Administration as a complementary diagnostic to provide PD-L1 status on patients who are considering treatment with the FDA approved Roche immunotherapy TECENTRIQ™ (atezolizumab) for metastatic urothelial cancer (mUC).